Morningstar

Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU

Provided by Dow Jones

By Colin Kellaher 




  Regeneron Pharmaceuticals and Sanofi have won expanded European regulatory approval of their blockbuster anti-inflammatory drug Dupixent for younger patients with the inflammatory skin condition chronic spontaneous urticaria, or CSU. 



  Regeneron and Sanofi on Monday said the green light from the European Commission covers Dupixent in children ages 2 to 11 with moderate-to-severe CSU, an inadequate response to histamine-1 antihistamines and who are naive to anti-immunoglobulin E therapy for CSU. 



  Regeneron and Sanofi last year won European approval of Dupixent for people 12 and older with CSU. 



  Tarrytown, N.Y., biotechnology company Regeneron created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement, while Sanofi markets the drug internationally. Dupixent global net sales reached about $18.5 billion last year. 





  Write to Colin Kellaher at colin.kellaher@wsj.com 





  (END) Dow Jones Newswires



  April 13, 2026 06:33 ET (10:33 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
 
Ask the Analyst columnist Amy Arnott answers a grab bag of reader questions about bond ETFs, TIPS, retirement planning, and more. 
 
 
Amy C. Arnott, CFA and Ivanna Hampton 
 
 
 
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
 
With a 3.3% dividend yield and earnings growth expected to exceed management’s outlook, this 4-star stock stands out in a struggling sector. 
 
 
Andrew Bischof, CFA, CPA 
 
 
 
The Thrilling 37
 
Just a few strict screens can narrow the field to an elite group of funds. 
 
 
Russel Kinnel 
 
 
 
3 Stocks to Invest In With More Room to Run
 
These stocks are up significantly in 2026, yet still look undervalued today. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center